Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report

Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report

Treatment-resistant schizophrenia (TRS) poses significant therapeutic challenges due to persistent symptoms, poor adherence, and high relapse rates. Long-acting injectable (LAI) antipsychotics offer a promising approach, yet limited evidence exists regarding the combination of two LAI formulations....

Full description

Saved in:

Bibliographic Details
Main Authors:	Salvatore Cipolla, Flora Delli Carpini, Pierluigi Catapano, Valeria De Santis, Antonio Volpicelli, Francesco Perris, Francesco Catapano
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Clinics and Practice
Subjects:	long-acting injectable antipsychotics treatment resistant schizophrenia case report
Online Access:	https://www.mdpi.com/2039-7283/15/3/55
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
by: de Bartolomeis A, et al.
Published: (2016-01-01)

Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al.

Enhanced treatment outcomes for schizophrenia through combined long-acting injectable antipsychotic medications and home visits: retrospective cohort study
by: Hiroyuki Harada, et al.
Published: (2025-09-01)

Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report
by: Xiaobo Xie, et al.
Published: (2025-01-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
by: Correll CU, et al.
Published: (2024-10-01)

Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms
by: Aleksandr M. Reznik, et al.
Published: (2024-12-01)

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies [Corrigendum]
by: Sajatovic M, et al.
Published: (2025-06-01)

Study of factors associated with obesity in patients using antipsychotics in schizophrenia
by: Vishalakshi Patnam, et al.
Published: (2024-12-01)

The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China
by: Huaning Wang, et al.
Published: (2025-07-01)

Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital
by: Isnenia Isnenia
Published: (2022-03-01)

Correction: The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans
by: Lilach Steiner, et al.
Published: (2025-01-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis
by: Hamilton JM, et al.
Published: (2025-06-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)

Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia
by: Mulualem Kelebie, et al.
Published: (2025-02-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

The Prevalence of Tardive Dyskinesia In Patients With Schizophrenia Treated With Antipsychotics In Malaysia
by: Nedunjelian A, et al.
Published: (2025-03-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
by: S. A. Galkin, et al.
Published: (2024-04-01)

Guideline for the use of therapeutic drug monitoring of antipsychotics to individualize the selection of therapy in the treatment of exacerbation of schizophrenia
by: S. S. Potanin, et al.
Published: (2023-12-01)

Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y)
by: Sofía Manchado Perero, et al.
Published: (2025-03-01)

Association of neutrophil-to-lymphocyte ratio with antipsychotic administration in schizophrenia: A longitudinal study
by: Rajnish Raj, et al.
Published: (2025-01-01)

Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia
by: Zheng Lan, et al.
Published: (2025-05-01)

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

Antipsychotic and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophreniaResearch in context
by: Siobhan K. Lock, et al.
Published: (2025-06-01)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
by: Anand E, et al.
Published: (2016-10-01)

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Haloperidol versus second-generation antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials
by: Daniel Prates Baldez, et al.
Published: (2025-05-01)

Depot Versus Oral Antipsychotics in Patients with Schizophrenia: Which is Better on Side Effects, Functional Improvement, and Life Satisfaction
by: İlknur Kiraz Avcı, et al.
Published: (2024-07-01)

The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study
by: Tobechukwu C. Iyidobi, et al.
Published: (2025-07-01)

The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia
by: Stefanović Vesna, et al.
Published: (2015-01-01)

Comparative Analysis of Time to All-cause Treatment Discontinuation and Rehospitalization among Early-phase Schizophrenia Patients Discharged on Long-acting Injectable Antipsychotics versus Oral Antipsychotics
by: Ta-Chun Lin, et al.
Published: (2025-01-01)

Virtual nurse support to enhance antipsychotic adherence in schizophrenia: A South African perspective
by: Yasmeen Thandar, et al.
Published: (2025-05-01)

One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians
by: Manchado Perero S, et al.
Published: (2025-05-01)